Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

Managing liver disease

New Content ItemLiver disease is on the increase and is the fifth leading cause of death in the UK. The patients often show symptoms only at advanced stages when it is too late to cure.

Liver diseases can be caused by a multitude of factors, including genetic predisposition, infections and the environment, therefore requiring diverse and targeted treatment options. The increasing incidence of some hepatic conditions worldwide is due to lifestyle actions, including alcohol intake and drug treatments. Concurrently, numerous infections and disorders are challenging to treat, as the causes and progression of a number of illnesses are not yet well understood.

Among others, liver cancer, hepatitis, non-alcoholic fatty liver disease and end-stage liver disease are being studied extensively to improve our understanding of the mechanisms of disease progression, and guide treatment decisions in terms of therapy selection and timing. Much of today’s focus on liver diseases is also on the development of more effective targeted treatments.

This upcoming article collection in BMC Medicine aims to feature the latest findings on the management of liver diseases, welcoming the submission of original research articles on the detection, management and new treatment techniques. Invited commentaries and reviews will also be included in the collection.

We would welcome direct submission of any original research within the collection scope – please submit directly to BMC Medicine stating in your cover letter that you are targeting the Managing liver disease collection. Alternatively please email your pre-submission queries to bmcmedicineeditorial@biomedcentral.com.

  1. Content type: Research article

    Direct-acting antivirals (DAAs) have revolutionized chronic hepatitis C (HCV) treatment, but real-world effectiveness among vulnerable populations, including uninsured patients, is lacking. This study was cond...

    Authors: Christina Yek, Carolina de la Flor, John Marshall, Cindy Zoellner, Grace Thompson, Lisa Quirk, Christian Mayorga, Barbara J. Turner, Amit G. Singal and Mamta K. Jain

    Citation: BMC Medicine 2017 15:204

    Published on:

  2. Content type: Correspondence

    We present two consensus definitions of advanced and late stage liver disease being used as epidemiological tools. These definitions can be applied to assess the morbidity caused by liver diseases in different...

    Authors: Stefan Mauss, Stanislas Pol, Maria Buti, Erika Duffell, Charles Gore, Jeffrey V. Lazarus, Hilje Logtenberg-van der Grient, Jens Lundgren, Antons Mozalevskis, Dorthe Raben, Eberhard Schatz, Stefan Wiktor and Jürgen K. Rockstroh

    Citation: BMC Medicine 2017 15:92

    Published on:

  3. Content type: Minireview

    Chronic hepatitis B virus (HBV) infection is a global public health issue. Although the disease cannot be cured effectively, disease management has been improved over the past decade. The introduction of poten...

    Authors: Tai-Chung Tseng and Jia-Horng Kao

    Citation: BMC Medicine 2017 15:53

    Published on:

  4. Content type: Minireview

    Non-alcoholic fatty liver disease has emerged a major challenge because of it prevalence, difficulties in diagnosis, complex pathogenesis, and lack of approved therapies. As the burden of hepatitis C abates ov...

    Authors: Brent A. Neuschwander-Tetri

    Citation: BMC Medicine 2017 15:45

    Published on:

Advertisement